Status:
TERMINATED
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Coronary Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.
Eligibility Criteria
Inclusion
- Are scheduled for primary CABG by median sternotomy involving cardiopulmonary bypass
- Willing to receive allogeneic blood product transfusions during and after surgery
Exclusion
- Have had previous cardiac surgery
- Have had previous median sternotomy
- Have tendency for bleeding or family history of bleeding
- Have an abnormally low platelet count
- Have received certain anticoagulant or antiplatelet medications within a specified time period prior to the scheduled CABG surgery
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00316212
Start Date
April 1 2006
Last Update
November 18 2016
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Baptist Medical Center Princeton
Birmingham, Alabama, United States, 35211
2
Cardiology, P.C.
Birmingham, Alabama, United States, 35211
3
Sharp Memorial Hospital
San Diego, California, United States, 92123
4
Memorial Medical Center
Springfield, Illinois, United States, 62702